Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice.
Luis O Chavez, Monica Leon, Sharon Einav...
https://pubmed.ncbi.nlm.nih.gov/27301374/Actively Recruiting
Led by Children's National Research Institute · Updated on 2025-07-03
50
Participants Needed
1
Research Sites
56 weeks
Total Duration
Researchers are studying the use of dexamethasone, a steroid, in addition to standard care for patients aged six months to 25 years diagnosed with rhabdomyolysis, a condition involving muscle breakdown. This study aims to evaluate whether adding dexamethasone improves pain, reduces hospital stay length, and lowers kidney complications. The trial is a blinded, randomized study conducted at a single center with up to 50 participants. Participants will be randomly assigned in a 21 ratio to receive either dexamethasone or a placebo once daily for five days, along with standard care. The dexamethasone dose is 0.6 mgkg per day, up to a maximum of 16 mg. Both groups will follow the same treatment duration and schedules, with no additional interventions beyond the study medication and standard care. During the study, patients and their caregivers may complete surveys assessing pain before and after treatment. Researchers will review medical records throughout and after the five-day treatment period to monitor muscle breakdown, kidney issues, and length of hospital stay. The primary outcomes include measuring these factors from five days up to one year, with pain outcomes assessed up to 14 days. The trial involves careful monitoring and no extra procedures beyond standard care and study medication.
CONDITIONS
Dexamethasone Use in Pediatric Rhabdomyolysis Patients in Addition to Standard Protocols
N
Natasha Shur, MD
N
Natasha Shur, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Children's National Research Institute
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Dexamethasone + Supportive Care | Placebo + Supportive Care | Supportive Care Only |
|---|---|---|---|
| What it is | Use of dexamethasone (steroid for five days) added to standard fluid and supportive care in children and young adults with rhabdomyolysis. | Use of placebo added to the same standard fluid and supportive care regimen in the trial population. | Fluid resuscitation and supportive management without steroid is the usual current standard care for pediatric rhabdomyolysis. |
| Role in trial | Randomly assigned investigational treatment arm. | Randomized control arm receiving placebo. | Not part of the trial but reflects standard clinical practice. |
| Primary use | To evaluate whether adding dexamethasone improves outcomes such as pain, length of stay, and kidney complications. | To serve as a control arm to compare with investigational treatment. | Represents the typical supportive-only management used outside the trial. |
| How it is given | Dexamethasone taken orally once daily for five days alongside standard care. | Matching oral placebo once daily for five days plus standard care. | Standard care involves fluid administration and supportive monitoring without oral steroid or placebo. |
| Evidence status | Effectiveness and safety of adding dexamethasone to standard care remain under investigation in this trial; limited case-level evidence exists. | Placebo added to supportive care serves as control; no inherent therapeutic effect is expected. | Supportive care is standard practice backed by clinical guidelines and observational evidence. |
| Important risks | Not yet established—potential risks of systemic steroid use in children are known but not trial-reported. | No additional risk beyond standard care is expected from placebo. | Safety profile is well established for fluid and supportive care. |
| Important limitations | Results are pending; single-center phase 1 study with small sample; dexamethasone use in rhabdomyolysis is investigational. | Also limited by trial size and center; placebo adds no therapeutic effect. | Supportive care alone may not address inflammatory pathways that dexamethasone targets; lacks trial-level comparative data. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 5 days
Participants receive either dexamethasone or placebo once daily for five days in addition to standard care.
Daily visits or assessments for 5 days
Duration - Up to 14 days after treatment
Participants and their caregivers may complete surveys before and after treatment to assess pain level and treatment improvement. Chart reviews will be performed throughout and after the treatment period.
1 to 2 visits depending on survey completion
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Luis O Chavez, Monica Leon, Sharon Einav...
https://pubmed.ncbi.nlm.nih.gov/27301374/Maxwell L Summerlin, Debra S Regier, Jamie L Fraser...
https://pubmed.ncbi.nlm.nih.gov/33300687/Heidi S Szugye
https://pubmed.ncbi.nlm.nih.gov/32482689/Children's National Research Institute
Lead Sponsor